Clinical Trial Update: Effect of Fimasartan for Modification of Atheroma Vulnerability in DEFERred Coronary Disease (FIMA-DEFER) [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating fimasartan for modification of atheroma vulnerability in patients with deferred coronary disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• Fimasartan (fimasartan)

Snippet

Sponsor: Seung-Jung Park | Conditions: Coronary Artery Disease | Phase 4 | Status: TERMINATED